Literature DB >> 29241681

Validation of Scratching Severity as an Objective Assessment for Itch.

Jeremy Udkoff1, Jonathan I Silverberg2.   

Abstract

There are currently no simple, standardized, objective assessments of itch for clinical trials and practice. We sought to validate and test the severity of scratching as an objective measure of itch (4-point ordinal scale ranging from 0 [not present] to 3 [very prominent] based on the observation of scratching lesions). We performed a prospective outpatient study using questionnaires and evaluations by a dermatologist in adults with atopic dermatitis (n = 261). Severity of scratching best correlated with patient-reported global atopic dermatitis severity (Kendall τ = 0.336, P < 0.0001), numeric rating scale of itch in the past 24 hours (τ = 0.266, P = 0.0010) and 3 days (τ = 0.296, P < 0.0001). Severity of scratching showed responsiveness over time. Patients experiencing improvement of scratching severity of 1 point or greater had significantly lower itch based on numeric rating scale in the past 3 days (Wilcoxon rank sum test, P = 0.0175), 5-D itch scale (P = 0.0146), and Patient-Oriented Eczema Measure scores (P = 0.0146). There was a significant decrease in scratching severity for patients experiencing itch improvement of 4 points or greater in the past 3 days on the numeric rating scale (Fisher exact test, P = 0.0026), Patient-Oriented Eczema Measure (P < 0.0001), and Dermatology Life Quality Index (P = 0.0285). Severity of scratching may be a useful endpoint in clinical trials and practice across the gamut of pruritic disorders. Future studies are needed to validate severity of scratching in other pruritic disease.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29241681     DOI: 10.1016/j.jid.2017.11.028

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  The pruritus severity scale-a novel tool to assess itch in burns patients.

Authors:  Suzanne M Beecher; Ronan Hill; Laura Kearney; Jemima Dorairaj; Arun Kumar; Anthony James Clover
Journal:  Int J Burns Trauma       Date:  2021-06-15

2.  PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models.

Authors:  Travis P Barr; Chris Garzia; Srijoy Guha; Elizabeth K Fletcher; Nga Nguyen; Adam J Wieschhaus; Lluis Ferrer; Lidija Covic; Athan Kuliopulos
Journal:  J Invest Dermatol       Date:  2018-10-01       Impact factor: 8.551

3.  Research Techniques Made Simple: Itch Measurement in Clinical Trials.

Authors:  Stephen Erickson; Brian S Kim
Journal:  J Invest Dermatol       Date:  2019-02       Impact factor: 8.551

4.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.